POS1519 BASELINE CHARACTERISTICS OF A LONGITUDINAL, MULTINATIONAL, MULTIETHNIC STUDY OF LUPUS PATIENTS, WITH OR WITHOUT LUPUS NEPHRITIS
Authors: R. Nieto, R. Quintana, E. Borba, L. Hernández, D. Fernández Ávila, L. F. Maurelli Torres, P. Alba, F. Bordon, F. Arizpe, G. Berbotto, R. Serrano Morales, M. C. Bertolaccini, E. Kerzberg, M. Gargiulo, A. Rodriguez, V. Barbosa, A. A. Gasparin, F. Cavalcanti, L. Alvino, L. P. Costa Seguro, L. De Oliveira Martins, O. Neira, L. Massardo, G. Aroca Martínez, I. Nieto Aristizabal, P. A. Mendez Patarroyo, A. Iglesias Gamarra, A. Zúñiga, O. L. Vera Lastra, M. Pérez Cristóbal, E. Martin-Nares, L. Amezcua-Guerra, Y. C. Gonzalez Bello, J. O. Gonzalez Enriquez, D. Á. Galarza-Delgado, C. Vázquez, M. Barrios, M. Alva, C. Reategui Sokolova, A. Quiróz Alva, T. Polanco Mora, C. Pizzarossa, M. Rebella, M. E. Crespo Espindola, A. Danza, E. Bonfa, G. S. Alarcon, F. Zazzetti, A. Orillion, U. Sbarigia, G. Pons-Estel
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. <h3>Objectives</h3> To describe sociodemographic, clinical, serological and treatment characteristics of a multicenter and multiethnic Latin American SLE cohort of patients with or without lupus nephritis (LN) <h3>Methods</h3> GLADEL2.0 is an ongoing observational cohort. Patients were categorized according to renal involvement: Group I (LN never); II (prevalent renal involvement currently inactive); III (prevalent renal involvement, currently active) and IV (incident renal involvement). Demographic, clinical manifestations, treatments, disease activity were examined at baseline. A descriptive cross-sectional analysis was performed. <h3>Results</h3> A total of 991 SLE patients were included, 884 (89.2%) female and 656 (68.3%) Mestizos (Amerindian and European ancestry). Median (IQR) age at cohort entry was 35 (28-45) years and disease duration were 67 months (18-139). Patients with incident LN had a higher proportion of males, were younger, had shorter disease duration and were more frequently Mestizos. Pericarditis and anti-dsDNA were less frequent in group I and MMF in groups I and IV (Table 1). A predominance of class IV (49%) was evidenced in 510 patients in which a kidney biopsy was performed. <h3>Conclusion</h3> Baseline characteristics of GLADEL2.0 well characterized lupus patients' cohort with or without LN are described with distinct demographic, clinical and laboratory patterns that will allow both centralized laboratory evaluation of urinary biomarkers and exploratory biomarker analyses including transcriptome and their impact on the outcome of these patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Romina Nieto: None declared, Rosana Quintana: None declared, Eduardo Borba: None declared, Lucia Hernández: None declared, Diana Fernández Ávila: None declared, Laura Fernanda Maurelli Torres: None declared, Paula Alba: None declared, Florencia Bordon: None declared, Fernando Arizpe: None declared, Guillermo Berbotto: None declared, Rosa Serrano Morales: None declared, María Constanza Bertolaccini: None declared, Eduardo Kerzberg: None declared, Maria Gargiulo: None declared, Anabella Rodriguez: None declared, Vitalina Barbosa: None declared, Andrese Aline Gasparin: None declared, Fernando Cavalcanti: None declared, Laissa Alvino: None declared, Luciana parente costa seguro: None declared, Lucas de Oliveira Martins: None declared, Oscar Neira: None declared, loreto massardo: None declared, Gustavo Aroca Martínez: None declared, Ivana Nieto Aristizabal: None declared, PAUL ALEJANDRO MENDEZ PATARROYO: None declared, Antonio Iglesias Gamarra: None declared, Andrés Zúñiga: None declared, Olga Lidia Vera Lastra: None declared, Mario Pérez Cristóbal: None declared, Eduardo Martin-Nares: None declared, Luis Amezcua-Guerra: None declared, YELITZA CONCEPCION GONZALEZ BELLO: None declared, Jose Octavio Gonzalez Enriquez: None declared, Dionicio Ángel Galarza-Delgado: None declared, Carolina Vázquez: None declared, Marcelo Barrios: None declared, Magaly Alva: None declared, Cristina Reategui Sokolova: None declared, Ana Quiróz Alva: None declared, Teresandris Polanco Mora: None declared, Carina Pizzarossa: None declared, Martin Rebella: None declared, Maria Elena Crespo Espindola: None declared, ALVARO DANZA: None declared, Eloisa Bonfa: None declared, Graciela S Alarcon: None declared, Federico Zazzetti Employee of: Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Horsham, PA, USA, Ashley Orillion Employee of: Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Spring House, PA, USA, Urbano Sbarigia Employee of: Janssen Pharmaceutica NV, Beerse, BE, Guillermo Pons-Estel: None declared.